These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 37629086)

  • 1. Ezrin Inhibition Overcomes Acquired Resistance to Vemurafenib in BRAFV600E-Mutated Colon Cancer and Melanoma Cells In Vitro.
    Car I; Dittmann A; Vasieva O; Bočkor L; Grbčić P; Piteša N; Klobučar M; Kraljević Pavelić S; Sedić M
    Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37629086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteomic Profiling of BRAFV600E Mutant Colon Cancer Cells Reveals the Involvement of Nucleophosmin/c-Myc Axis in Modulating the Response and Resistance to BRAF Inhibition by Vemurafenib.
    Grbčić P; Fučkar Čupić D; Gamberi T; Kraljević Pavelić S; Sedić M
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34201061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Sphingosine Kinase 2 Inhibitor ABC294640 Restores the Sensitivity of BRAFV600E Mutant Colon Cancer Cells to Vemurafenib by Reducing AKT-Mediated Expression of Nucleophosmin and Translationally-Controlled Tumour Protein.
    Grbčić P; Eichmann TO; Kraljević Pavelić S; Sedić M
    Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polyamine and EIF5A hypusination downstream of c-Myc confers targeted therapy resistance in BRAF mutant melanoma.
    Park BS; Jeon H; Kim Y; Kwon H; Choi GE; Chi SG; Park HM; Lee H; Kim T
    Mol Cancer; 2024 Jul; 23(1):136. PubMed ID: 38965534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unusually long-term responses to vemurafenib in BRAF V600E mutated colon and thyroid cancers followed by the development of rare RAS activating mutations.
    Ofir Dovrat T; Sokol E; Frampton G; Shachar E; Pelles S; Geva R; Wolf I
    Cancer Biol Ther; 2018; 19(10):871-874. PubMed ID: 30036146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mitochondrial complex I inhibitor deguelin induces metabolic reprogramming and sensitizes vemurafenib-resistant BRAF
    Carpenter EL; Chagani S; Nelson D; Cassidy PB; Laws M; Ganguli-Indra G; Indra AK
    Mol Carcinog; 2019 Sep; 58(9):1680-1690. PubMed ID: 31211467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioenergetic modulation with dichloroacetate reduces the growth of melanoma cells and potentiates their response to BRAFV600E inhibition.
    Abildgaard C; Dahl C; Basse AL; Ma T; Guldberg P
    J Transl Med; 2014 Sep; 12():247. PubMed ID: 25182332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistance to vemurafenib resulting from a novel mutation in the BRAFV600E kinase domain.
    Wagenaar TR; Ma L; Roscoe B; Park SM; Bolon DN; Green MR
    Pigment Cell Melanoma Res; 2014 Jan; 27(1):124-33. PubMed ID: 24112705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic Efficacy of Pharmacological Ascorbate on Braf Inhibitor Resistant Melanoma Cells In Vitro and In Vivo.
    Niessner H; Burkard M; Leischner C; Renner O; Plöger S; Meraz-Torres F; Böcker M; Hirn C; Lauer UM; Venturelli S; Busch C; Sinnberg T
    Cells; 2022 Apr; 11(7):. PubMed ID: 35406796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of BRAF V600 mutation in melanoma.
    Ascierto PA; Kirkwood JM; Grob JJ; Simeone E; Grimaldi AM; Maio M; Palmieri G; Testori A; Marincola FM; Mozzillo N
    J Transl Med; 2012 Jul; 10():85. PubMed ID: 22554099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p53 Reactivation by PRIMA-1(Met) (APR-246) sensitises (V600E/K)BRAF melanoma to vemurafenib.
    Krayem M; Journe F; Wiedig M; Morandini R; Najem A; Salès F; van Kempen LC; Sibille C; Awada A; Marine JC; Ghanem G
    Eur J Cancer; 2016 Mar; 55():98-110. PubMed ID: 26790143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resveratrol Overcomes Cellular Resistance to Vemurafenib Through Dephosphorylation of AKT in BRAF-mutated Melanoma Cells.
    Luo H; Umebayashi M; Doi K; Morisaki T; Shirasawa S; Tsunoda T
    Anticancer Res; 2016 Jul; 36(7):3585-9. PubMed ID: 27354627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. S100A4 Knockout Sensitizes Anaplastic Thyroid Carcinoma Cells Harboring BRAFV600E/Mt to Vemurafenib.
    Jiao X; Zhang H; Xu X; Yu Y; Zhang H; Zhang J; Ning L; Hao F; Liu X; Niu M; Chen CT; Chen D; Zhang K
    Cell Physiol Biochem; 2018; 49(3):1143-1162. PubMed ID: 30196299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Novel Plant Sesquiterpene Lactone Derivative, DETD-35, Suppresses BRAFV600E Mutant Melanoma Growth and Overcomes Acquired Vemurafenib Resistance in Mice.
    Feng JH; Nakagawa-Goto K; Lee KH; Shyur LF
    Mol Cancer Ther; 2016 Jun; 15(6):1163-76. PubMed ID: 27048951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Progress of anti-tumor study based on BRAF].
    Yan GR; Xu ZJ; Wang HY; Zhu WL
    Yao Xue Xue Bao; 2012 Dec; 47(12):1567-74. PubMed ID: 23460959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic inhibitors eliminate senescent melanoma BRAFV600E cells that survive long‑term BRAF inhibition.
    Madorsky Rowdo FP; Barón A; Gallagher SJ; Hersey P; Emran AA; Von Euw EM; Barrio MM; Mordoh J
    Int J Oncol; 2020 Jun; 56(6):1429-1441. PubMed ID: 32236593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resistance to BRAF Inhibitors: EZH2 and Its Downstream Targets as Potential Therapeutic Options in Melanoma.
    Uebel A; Kewitz-Hempel S; Willscher E; Gebhardt K; Sunderkötter C; Gerloff D
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting CDC7 sensitizes resistance melanoma cells to BRAF
    Gad SA; Ali HEA; Gaballa R; Abdelsalam RM; Zerfaoui M; Ali HI; Salama SH; Kenawy SA; Kandil E; Abd Elmageed ZY
    Sci Rep; 2019 Oct; 9(1):14197. PubMed ID: 31578454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations.
    Niehr F; von Euw E; Attar N; Guo D; Matsunaga D; Sazegar H; Ng C; Glaspy JA; Recio JA; Lo RS; Mischel PS; Comin-Anduix B; Ribas A
    J Transl Med; 2011 May; 9():76. PubMed ID: 21609436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vemurafenib potently induces endoplasmic reticulum stress-mediated apoptosis in BRAFV600E melanoma cells.
    Beck D; Niessner H; Smalley KS; Flaherty K; Paraiso KH; Busch C; Sinnberg T; Vasseur S; Iovanna JL; Drießen S; Stork B; Wesselborg S; Schaller M; Biedermann T; Bauer J; Lasithiotakis K; Weide B; Eberle J; Schittek B; Schadendorf D; Garbe C; Kulms D; Meier F
    Sci Signal; 2013 Jan; 6(260):ra7. PubMed ID: 23362240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.